Graph takes few seconds to load...
Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of novel therapeutics that target the endocannabinoid system in the fields of autoimmunity, fibrosis, and cancer.
Its lead product candidate is lenabasum, a cannabinoid receptor type 2 (CB2) that is in Phase III clinical trial for the treatment of dermatomyositis; and in Phase II clinical trial to treat systemic lupus erythematosus.
The company is also developing cannabinoid receptor type 1 inverse agonist program for treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; and CB2 agonist program for the treatment of cancer.
It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, which includes the Jenrin library of approximately 600 compounds and multiple issued and pending patent filings; and strategic collaboration with Kaken Pharmaceutical Co., Ltd. for the development and commercialization of lenabasum in Japan. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
| Annual Data | Millions of US $ except per share data | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 |
|---|---|---|---|---|---|---|---|---|
| Cash on hand | $31.75 | $41.75 | $62.54 | $14.99 | $12.34 | - | - | - |
| Receivables | $2.68 | - | - | $1 | - | $1.33 | - | - |
| Inventory | - | - | $0 | $0 | $0 | $0 | - | - |
| Pre-Paid Expenses | - | - | - | - | - | - | - | - |
| Other Current Assets | $3.72 | $2.49 | $2.81 | $1.26 | $0.38 | $0.27 | $0300000 | - |
| Total Current Assets | $38.15 | $44.24 | $65.50 | $17.40 | $12.71 | $6.53 | - | - |
| Property, Plant, And Equipment | $10.90 | $2.71 | $1.43 | $0.44 | $0.12 | $0.05 | - | - |
| Long-Term Investments | - | - | - | - | - | - | - | - |
| Goodwill And Intangible Assets | - | - | $0 | $0 | $0 | $0 | - | - |
| Other Long-Term Assets | $0.08 | $0.04 | $0.04 | $0.05 | $0.04 | $0.01 | - | - |
| Total Long-Term Assets | $10.99 | $2.75 | $1.47 | $0.49 | $0.16 | - | - | - |
| Total Assets | $49.14 | $46.99 | $66.98 | $17.89 | $12.88 | $6.60 | $0.31 | - |
| Total Current Liabilities | $34.89 | $18.09 | $8.20 | $8.90 | $3.63 | $0.74 | $0.65 | - |
| Long Term Debt | - | - | $0 | $0500000 | $0 | $0 | $0.33 | - |
| Other Non-Current Liabilities | - | $1.38 | $0.99 | $0.07 | $0.26 | $0463200 | - | - |
| Total Long Term Liabilities | $8.10 | $1.38 | $0.99 | $0.07 | $0.26 | - | - | - |
| Total Liabilities | $42.98 | $19.47 | $9.19 | $8.97 | $3.89 | $0.74 | $0.98 | - |
| Common Stock Net | $0646700 | $0572500 | $0556000 | $0446800 | $0376100 | $0300000 | $0100000 | - |
| Retained Earnings (Accumulated Deficit) | $-192.82 | $-121.37 | $-65.70 | $-33.28 | $-13.28 | $-4.43 | - | - |
| Comprehensive Income | - | - | $0 | $0 | $0 | $5.86 | - | - |
| Other Share Holders Equity | - | - | - | - | - | - | - | - |
| Share Holder Equity | $6.16 | $27.52 | $57.78 | $8.92 | $8.99 | $5.86 | - | - |
| Total Liabilities And Share Holders Equity | $49.14 | $46.99 | $66.98 | $17.89 | $12.88 | - | - | - |
